Antiphospholipid syndrome (APS) is an autoimmune condition characterized by hypercoagulability often manifested as recurrent thrombosis or pregnancy complications, with persistently circulating antiphospholipid (aPL) antibodies or lupus anticoagulant. Catastrophic APS (CAPS), also known as Asherson syndrome, occurs in less than 1% of cases of APS and involves occlusive microangiopathy in at least three organ systems.1 Case…
Follow-up Visit with Time A 62-year-old male patient returns to the office for a follow-up visit for chronic idiopathic gout without tophi. The patient’s present uric acid level is 4.0, and he is now taking allopurinol 450 mg per day. Previously, he was taken off indapamide due to an increase in his uric acid. He…
The FDA is investigating the safety of MRIs using gadolinium-based contrast agents, which recent studies have shown may leave deposits of those chemicals in patients’ brain tissue after multiple scans…
LONDON (Reuters)—Drug industry productivity is continuing to improve, with a bumper haul of new products being launched and companies proving more successful in the final stages of clinical testing, according to a new analysis. Data from Thomson Reuters published on Tuesday showed the number of innovative medicines, or new molecular entities, launched globally in 2014…
BEIJING (Reuters)—China will expand medical insurance to cover all critical illnesses for all urban and rural residents by the end of the year, the cabinet said on Sunday, the latest step in a plan to fix a healthcare system that has sparked public discontent. The State Council said 50% of the medical costs will be…
Researchers in the U.K. have discovered that manipulating T cells to exhaustion in a targeted way may lead to new treatments and predictors for various types of autoimmune diseases…
In a survey, the Coalition of State Rheumatology Organizations found a consensus among rheumatologists that the FDA should increase safety for biosimilar therapies via naming and labeling regulations…
(Reuters Health)—Media reports raising safety concerns about osteoporosis drugs known as bisphosphonates may have contributed to a sharp drop in their use—even though U.S. doctors and drug regulators haven’t recommended against taking them, a study suggests. Fosamax (alendronate sodium) won U.S. marketing approval in 1995. Widespread use of the drug and others like it over…
NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) does not increase the risk of malignancies, according to pooled data from more than 5000 rheumatoid arthritis (RA) patients. In an April 22 online paper in Annals of the Rheumatic Diseases, Dr. Lisy Wang of Pfizer, Groton, Connecticut, and colleagues noted that in RA…
Telling a patient that he or she has been diagnosed with rheumatoid arthritis (RA), ankylosing spondylitis, fibromyalgia or another debilitating, painful and/or chronic condition can be upsetting for a patient to hear and difficult for a rheumatologist to convey. Given this, it’s important to prepare for the appointment. “Take a few minutes beforehand to contemplate…